A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 2, 2006, Pages 799-808

  Fu, Yun Feng ^a   Zhu, Yi Na ^a   Ni, Jia ^a   Zhong, Xiang Gen ^a   Tang, Wei ^a   Re, Yu Dan ^a   Shi, Li Ping ^a   Wan, Jin ^a   Yang, Yi Fu ^a   Yuan, Chong ^c   Nan, Fa Jun ^a   Lawson, Brian R ^c   Zuo, Jian Ping ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Diazyme Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DZ 2002; HYDROLASE INHIBITOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN P27; S ADENOSYLHOMOCYSTEINE HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADENINE; ADENOSYLHOMOCYSTEINASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD3; BUTYRIC ACIDS; CELL CYCLE; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; FEMALE; GLYCOPROTEINS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 33751167243     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.107185     Document Type: Article

References (34)

1. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197:725-733.
2. Alberola-Ila J, Takaki S, Kerner JD, and Perlmutter RM (1997) Differential signaling by lymphocyte antigen receptors. Annu Rev Immunol 15:125-154.
3. Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, and Boussiotis VA (2002) CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 168:2729-2736.
4. Bright JJ, Du C, and Sriram S (1999) Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol 162:6255-6262.
5. Craner MJ, Damarjian TG, Liu S, Hains BC, Lo AC, Black JA, Newcombe J, Cuzner ML, and Waxman SG (2005) Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49:220-229.
6. Dean G (1994) How many people in the world have multiple sclerosis. Neuroepidemiology 13:1-7.
7. Fu YF, Wang JX, Zhao Y, Yang Y, Tang W, Ni J, Zhu YN, Zhou R, He PL, Li C, et al. (2006) S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses. J Pharmacol Exp Ther 316:1229-1237.
8. German DC, Bloch CA, and Kredich NM (1983) Measurements of S-adenosylmethionine and L-homocysteine metabolism in cultured human lymphoid cells. J Biol Chem 258:10997-11003.
9. Huitinga I, van Rooijen N, de Groot CJ, Uitdehaag BM, and Dijkstra CD (1990) Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J Exp Med 172:1025-1033.
10. 0 T cells. J Immunol 158:5642-5648.
11. Liu JS, Zhao ML, Brosnan CF, and Lee SC (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158:2057-2066.
12. Lovett-Racke AE, Rocchini AE, Choy J, Northrop SC, Hussain RZ, Ratts RB, Sikder D, and Racke MK (2004) Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 21:719-731.
13. Matsumoto Y, Ohmori K, and Fujiwara M (1992) Immune regulation by brain cells in the central nervous system: microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76:209-216.
14. Nagasawa M, Melamed I, Kupfer A, Gelfand EW, and Lucas JJ (1997) Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation. J Immunol 158:5146-5154.
15. Nath N, Giri S, Prasad R, Singh AK, and Singh I (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273-1286.
16. Natarajan C and Bright JJ (2002) Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168:6506-6513.
17. Nelson BH and Willerford DM (1998) Biology of the interleukin-2 receptor. Adv Immunol 70:1-81.
18. Panitch HS, Hirsch RL, Haley AS, and Johnson KP (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893-895.
19. Sakurai K, Zou JP, Tschetter JR, Ward JM, and Shearer GM (2002) Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. J Neuroimmunol 129:186-196.
20. Saso Y, Conner EM, Teegarden BR, and Yuan CS (2001) S-adenosyl-L- homocysteine hydrolase inhibitor mediates immunosuppressive effects in vivo: suppression of delayed type hypersensitivity ear swelling and peptidoglycan polysaccharide-induced arthritis. J Pharmacol Exp Ther 296:106-112.
21. 1-phase progression. Genes Dev 13:1501-1512.
22. Sospedra M and Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683-747.
23. Suen WE, Bergman CM, Hjelmstrom P, and Ruddle NH (1997) A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 186:1233-1240.
24. Wolos JA, Frondorf KA, Babcock GF, Stripp SA, and Bowlin TL (1993a) Immunomodulation by an inhibitor of S-adenosyl-L-homocysteine hydrolase: inhibition of in vitro and in vivo allogeneic responses. Cell Immunol 149:402-408.
25. Wolos JA, Frondorf KA, Davis GF, Jarvi ET, McCarthy JR, and Bowlin TL (1993b) Selective inhibition of T cell activation by an inhibitor of S-adenosyl-L-homocysteine hydrolase. J Immunol 150:3264-3273.
26. Wolos JA, Frondorf KA, and Esser RE (1993c) Immunosuppression mediated by an inhibitor of S-adenosyl-L-homocysteine hydrolase: prevention and treatment of collagen-induced arthritis. J Immunol 151:526-534.
27. Wu QL, Fu YF, Zhou WL, Wang JX, Feng YH, Liu J, Xu JY, He PL, Zhou R, Tang W, et al. (2005) Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther 313:705-711.
28. Yang YF, Mukai T, Gao P, Yamaguchi N, Ono S, Iwaki H, Obika S, Imanishi T, Tsujimura T, Hamaoka T, et al. (2002) A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anticollagen T cell responses. Eur J Immunol 32:2124-2132.
29. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (Lond) 420:78-84.
30. Yuan CS, Saso Y, Lazarides E, Borchardt RT, and Robins MJ (1999) Recent advances in S-adenosyl-L-homocysteine hydrolase inhibitors and their potential clinical applications. Exp Opin Ther Patents 9:1197-1206.
31. Zamvil SS and Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 8:579-621.
32. + T cells. J Immunol 164:2296-2302.
33. Zhu YN, Zhao WM, Yang YF, Liu QF, Zhou Y, Tian J, Ni J, Fu YF, Zhong XG, Tang W, et al. (2006) Periplocoside E, an effective compound from Periploca sepium Bge, inhibited T cell activation in vitro and in vivo. J Pharmacol Exp Ther 316:662-669.
34. Zindy F, van Deursen J, Grosveld G, Sherr CJ, and Roussel MF (2000) INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20:372-378.